I
ITOS
Iteos Therapeutics, Inc.
This stock has been delisted.
News
Press Releases
Financial Reports
Profile
Reuters·09/02/2025 12:01
Vor Biopharma Inc. Appoints Adi Osovsky as General Counsel to Support Strategic Growth
Dow Jones·08/29/2025 21:08
*News On iTeos Therapeutics Inc. (ITOS) Now Under CBIO.XX
TipRanks·08/29/2025 13:25
iTeos Therapeutics Completes Merger with Concentra Biosciences
Reuters·08/29/2025 13:01
Iteos Therapeutics Announces Delisting from Nasdaq Following Merger Completion
TipRanks·08/15/2025 16:25
GSK and iTeos Advance Immunotherapy Study for Lung Cancer
TipRanks·08/08/2025 16:18
GSK and iTeos Therapeutics’ Promising Phase 3 Lung Cancer Study: Market Implications
Reuters·08/07/2025 19:29
Iteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
TipRanks·08/07/2025 15:36
Wells Fargo Sticks to Its Hold Rating for iTeos Therapeutics (ITOS)
Dow Jones·08/07/2025 14:58
iTeos Therapeutics Price Target Cut to $11.00/Share From $12.00 by Wells Fargo
Dow Jones·08/07/2025 14:58
iTeos Therapeutics Is Maintained at Equal-Weight by Wells Fargo
Benzinga·08/07/2025 14:48
Wells Fargo Maintains Equal-Weight on ITeos Therapeutics, Lowers Price Target to $11
Reuters·08/07/2025 11:15
ITEOS THERAPEUTICS. INC. <ITOS.O>: WELLS FARGO CUTS TARGET PRICE TO $11 FROM $12
Reuters·08/07/2025 07:56
U.S. RESEARCH ROUNDUP-Applovin, Costco Wholesale, Hubspot
TipRanks·08/07/2025 05:03
iTeos Therapeutics Faces Challenges Amid Collaboration Termination
Benzinga·08/06/2025 12:32
ITeos Therapeutics Q2 EPS $(1.81) Misses $(0.95) Estimate
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.